TWI799849B - 治療或預防偏頭痛之方法 - Google Patents
治療或預防偏頭痛之方法 Download PDFInfo
- Publication number
- TWI799849B TWI799849B TW110115984A TW110115984A TWI799849B TW I799849 B TWI799849 B TW I799849B TW 110115984 A TW110115984 A TW 110115984A TW 110115984 A TW110115984 A TW 110115984A TW I799849 B TWI799849 B TW I799849B
- Authority
- TW
- Taiwan
- Prior art keywords
- treating
- methods
- migraine headache
- preventing migraine
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Treatment And Processing Of Natural Fur Or Leather (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152708P | 2015-04-24 | 2015-04-24 | |
US62/152,708 | 2015-04-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202130369A TW202130369A (zh) | 2021-08-16 |
TWI799849B true TWI799849B (zh) | 2023-04-21 |
Family
ID=53969433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110115984A TWI799849B (zh) | 2015-04-24 | 2015-08-07 | 治療或預防偏頭痛之方法 |
TW104125845A TWI728953B (zh) | 2015-04-24 | 2015-08-07 | 治療或預防偏頭痛之方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104125845A TWI728953B (zh) | 2015-04-24 | 2015-08-07 | 治療或預防偏頭痛之方法 |
Country Status (30)
Country | Link |
---|---|
US (3) | US10259877B2 (zh) |
EP (2) | EP3285803B1 (zh) |
JP (4) | JP6392471B2 (zh) |
KR (1) | KR102464415B1 (zh) |
CN (2) | CN113908268A (zh) |
AU (2) | AU2015392215B2 (zh) |
BR (1) | BR112017022772A2 (zh) |
CA (1) | CA2984254C (zh) |
CL (1) | CL2017002686A1 (zh) |
CY (1) | CY1123211T1 (zh) |
DK (1) | DK3285803T3 (zh) |
ES (1) | ES2771925T3 (zh) |
HK (1) | HK1250914A1 (zh) |
HR (1) | HRP20200056T1 (zh) |
HU (1) | HUE048528T2 (zh) |
IL (2) | IL255114B (zh) |
JO (2) | JOP20200116A1 (zh) |
LT (1) | LT3285803T (zh) |
MA (2) | MA51815A (zh) |
MX (2) | MX2017013627A (zh) |
PH (1) | PH12017501934A1 (zh) |
PL (1) | PL3285803T3 (zh) |
PT (1) | PT3285803T (zh) |
RS (1) | RS59912B1 (zh) |
RU (1) | RU2707745C2 (zh) |
SG (2) | SG10202004282RA (zh) |
SI (1) | SI3285803T1 (zh) |
TW (2) | TWI799849B (zh) |
WO (1) | WO2016171742A1 (zh) |
ZA (1) | ZA201707179B (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
KR20190066607A (ko) | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
US20190071490A1 (en) | 2017-03-02 | 2019-03-07 | Beth Israel Deaconess Medical Center, Inc. | Preventing Post-Ictal Headaches |
WO2019055399A1 (en) * | 2017-09-12 | 2019-03-21 | Igc Bio, Inc. | ANTI-VEGF ANTIBODIES |
TWI831762B (zh) | 2018-01-12 | 2024-02-11 | 美商安進公司 | Pac1抗體及其用途 |
JP2021519790A (ja) * | 2018-04-02 | 2021-08-12 | アムジェン インコーポレイテッド | エレヌマブ組成物及びその使用 |
AU2019299676A1 (en) | 2018-07-05 | 2021-01-28 | Allergan Pharmaceuticals International Limited | Combination therapy with CGRP antagonists and Clostridial derivatives |
MX2021008267A (es) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. |
SG11202110637RA (en) * | 2019-05-02 | 2021-10-28 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
US20210130445A1 (en) | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders |
WO2021005494A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
WO2021005497A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders |
US11607395B2 (en) * | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
WO1993019180A1 (en) | 1992-03-17 | 1993-09-30 | Ciba-Geigy Ag | Genetically engineered antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | カルシトニンレセプター |
US5785682A (en) | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU6596096A (en) | 1996-07-23 | 1998-02-10 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
FR2821080B1 (fr) | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques |
ATE453661T1 (de) | 2001-09-27 | 2010-01-15 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
KR101070213B1 (ko) | 2002-08-12 | 2011-10-06 | 액타비스 그룹 에이취에프. | 건선 치료를 위한 cgrp 안타고니스트 화합물의 용도 |
US20040176577A1 (en) | 2002-09-10 | 2004-09-09 | Eva Rojer | Immunoassays for specific determination of SCCA isoforms |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
CN1961000B (zh) | 2004-02-11 | 2011-05-04 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
US7973140B2 (en) | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
DE102004063753A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
CN101232897A (zh) | 2005-06-16 | 2008-07-30 | 新藤隆行 | 含有肾上腺髓质素作为有效成分的血管生成剂 |
GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
CN101309704B (zh) * | 2005-11-14 | 2012-10-10 | 礼纳特神经***科学公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
JP2009515973A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロラクタム三環式cgrp受容体アンタゴニスト |
WO2007076336A1 (en) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
CA2650932C (en) | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
AU2007348941B2 (en) | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
US8372859B2 (en) | 2007-04-11 | 2013-02-12 | Merck, Sharp & Dohme Corp. | CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups |
EP2146712A4 (en) | 2007-04-16 | 2010-10-13 | Merck Sharp & Dohme | ANTAGONISTS OF ARYL HETEROCYCLIC CGRP RECEPTORS |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
KR101304085B1 (ko) | 2008-03-04 | 2013-09-05 | 라브리스 바이올로직스 인코포레이티드 | 염증성 통증의 치료 방법 |
AU2009257733A1 (en) | 2008-06-12 | 2009-12-17 | Merck Sharp & Dohme Corp. | Branched 3- and 6-substituted quinolines as CGRP receptor antagonists |
FR2934597B1 (fr) | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
AU2009293471A1 (en) | 2008-09-18 | 2010-03-25 | Merck Sharp & Dohme Corp. | Bicyclic dihydroimidazolone CGRP receptor antagonists |
JP2012504625A (ja) | 2008-10-03 | 2012-02-23 | メルク・シャープ・エンド・ドーム・コーポレイション | Cgrp受容体アンタゴニスト |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
AU2010288194B2 (en) | 2009-08-28 | 2013-08-29 | Teva Pharmaceuticals International Gmbh | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
AR081434A1 (es) | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
JOP20190250A1 (ar) * | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
AU2012258976B8 (en) * | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
HUE055505T2 (hu) | 2011-05-20 | 2021-11-29 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
DK2709663T3 (da) * | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
ES2770976T3 (es) | 2013-03-15 | 2020-07-06 | Amgen Inc | Anticuerpos PAC1 humanos |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
AU2015318008B2 (en) * | 2014-09-15 | 2021-05-20 | Amgen Inc. | Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof |
-
2015
- 2015-04-24 JO JOP/2020/0116A patent/JOP20200116A1/ar unknown
- 2015-08-07 TW TW110115984A patent/TWI799849B/zh active
- 2015-08-07 TW TW104125845A patent/TWI728953B/zh active
- 2015-08-10 MX MX2017013627A patent/MX2017013627A/es unknown
- 2015-08-10 SI SI201531065T patent/SI3285803T1/sl unknown
- 2015-08-10 PL PL15754071T patent/PL3285803T3/pl unknown
- 2015-08-10 HU HUE15754071A patent/HUE048528T2/hu unknown
- 2015-08-10 CN CN202110748961.0A patent/CN113908268A/zh active Pending
- 2015-08-10 CN CN201580081186.0A patent/CN108156814B/zh active Active
- 2015-08-10 RS RS20200165A patent/RS59912B1/sr unknown
- 2015-08-10 PT PT157540717T patent/PT3285803T/pt unknown
- 2015-08-10 EP EP15754071.7A patent/EP3285803B1/en active Active
- 2015-08-10 KR KR1020177034051A patent/KR102464415B1/ko active IP Right Grant
- 2015-08-10 MA MA051815A patent/MA51815A/fr unknown
- 2015-08-10 WO PCT/US2015/044479 patent/WO2016171742A1/en active Application Filing
- 2015-08-10 JP JP2017555506A patent/JP6392471B2/ja active Active
- 2015-08-10 ES ES15754071T patent/ES2771925T3/es active Active
- 2015-08-10 SG SG10202004282RA patent/SG10202004282RA/en unknown
- 2015-08-10 BR BR112017022772-0A patent/BR112017022772A2/pt not_active Application Discontinuation
- 2015-08-10 RU RU2017140789A patent/RU2707745C2/ru active
- 2015-08-10 MA MA41932A patent/MA41932B1/fr unknown
- 2015-08-10 CA CA2984254A patent/CA2984254C/en active Active
- 2015-08-10 EP EP19212188.7A patent/EP3653225A1/en active Pending
- 2015-08-10 LT LTEP15754071.7T patent/LT3285803T/lt unknown
- 2015-08-10 SG SG11201708607WA patent/SG11201708607WA/en unknown
- 2015-08-10 DK DK15754071.7T patent/DK3285803T3/da active
- 2015-08-10 AU AU2015392215A patent/AU2015392215B2/en active Active
-
2016
- 2016-03-03 JO JOP/2016/0034A patent/JO3559B1/ar active
- 2016-04-22 US US15/136,736 patent/US10259877B2/en active Active
-
2017
- 2017-10-18 IL IL255114A patent/IL255114B/en unknown
- 2017-10-23 MX MX2021013327A patent/MX2021013327A/es unknown
- 2017-10-23 PH PH12017501934A patent/PH12017501934A1/en unknown
- 2017-10-23 ZA ZA2017/07179A patent/ZA201707179B/en unknown
- 2017-10-23 CL CL2017002686A patent/CL2017002686A1/es unknown
-
2018
- 2018-08-10 HK HK18110282.6A patent/HK1250914A1/zh unknown
- 2018-08-21 JP JP2018154482A patent/JP6707590B2/ja active Active
-
2019
- 2019-02-27 US US16/287,533 patent/US11466090B2/en active Active
-
2020
- 2020-01-14 HR HRP20200056TT patent/HRP20200056T1/hr unknown
- 2020-02-11 CY CY20201100128T patent/CY1123211T1/el unknown
- 2020-05-20 JP JP2020087893A patent/JP2020143115A/ja active Pending
-
2022
- 2022-03-07 IL IL291153A patent/IL291153B2/en unknown
- 2022-06-14 JP JP2022095538A patent/JP2022126724A/ja active Pending
- 2022-07-06 AU AU2022204866A patent/AU2022204866A1/en active Pending
- 2022-09-02 US US17/902,168 patent/US20230020514A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291153A (en) | Methods for treating or preventing migraine headaches | |
EP3500289A4 (en) | METHODS OF TREATING TRACHEOBRONCHOMALACIA | |
EP3288382A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3113736A4 (en) | Method for treatment of migraine and other headaches | |
IL265335A (en) | Treating cluster headache | |
EP3286311A4 (en) | Method for the treatment of malignancies | |
EP3171878A4 (en) | Methods for treating paramyxoviruses | |
EP3229808A4 (en) | Methods for treating fungal infections | |
EP3226967A4 (en) | Methods and systems for preventative migraine headache treatment | |
EP3110509A4 (en) | Method for treating cancer | |
EP3220916A4 (en) | Method for treating cancer | |
EP3206688A4 (en) | Method for treating cancer | |
EP3341080A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3389634A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
EP3242947A4 (en) | Method for the treatment of malignancies | |
EP3484515A4 (en) | METHOD FOR TREATING FIBROSE | |
EP3389652A4 (en) | METHODS OF TREATING CANCER | |
EP3154546A4 (en) | Methods for treating pruritus | |
EP3448365A4 (en) | CONSTIPATION TREATMENT METHOD | |
EP3334432A4 (en) | CERDULATINIB FOR THE TREATMENT OF MYELOMA | |
EP3260119A4 (en) | Combination method for treating cancer | |
EP3194025A4 (en) | Methods for preventing or treating osteoarthritis | |
EP3247376A4 (en) | Method for treating cancer | |
AU2015305430B2 (en) | Method for treating hyperhidrosis | |
EP3250218A4 (en) | Methods for treating obesity |